BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ettrich TJ, Schwerdel D, Dolnik A, Beuter F, Blätte TJ, Schmidt SA, Stanescu-Siegmund N, Steinacker J, Marienfeld R, Kleger A, Bullinger L, Seufferlein T, Berger AW. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep 2019;9:13261. [PMID: 31519967 DOI: 10.1038/s41598-019-49860-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Vera R, Ibarrola-de-Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. Clin Transl Oncol 2022. [PMID: 36008616 DOI: 10.1007/s12094-022-02873-0] [Reference Citation Analysis]
2 Madoff DC, Abi-Jaoudeh N, Braxton D, Goyal L, Jain D, Odisio BC, Salem R, Schattner M, Sheth R, Li D. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. Oncologist 2022:oyac139. [PMID: 35925597 DOI: 10.1093/oncolo/oyac139] [Reference Citation Analysis]
3 Kirchweger P, Wundsam HV, Rumpold H. Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies. World J Clin Oncol 2022; 13(6): 473-484 [DOI: 10.5306/wjco.v13.i6.473] [Reference Citation Analysis]
4 Arechederra M, Rullán M, Amat I, Oyon D, Zabalza L, Elizalde M, Latasa MU, Mercado MR, Ruiz-Clavijo D, Saldaña C, Fernández-Urién I, Carrascosa J, Jusué V, Guerrero-Setas D, Zazpe C, González-Borja I, Sangro B, Herranz JM, Purroy A, Gil I, Nelson LJ, Vila JJ, Krawczyk M, Zieniewicz K, Patkowski W, Milkiewicz P, Cubero FJ, Alkorta-Aranburu G, G Fernandez-Barrena M, Urman JM, Berasain C, Avila MA. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut 2022;71:1141-51. [PMID: 34285068 DOI: 10.1136/gutjnl-2021-325178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
5 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022:gutjnl-2022-327099. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Alese OB, Cook N, Ortega-Franco A, Ulanja MB, Tan L, Tie J. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. Am Soc Clin Oncol Educ Book 2022;42:1-20. [PMID: 35471832 DOI: 10.1200/EDBK_349143] [Reference Citation Analysis]
7 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
8 Mocan LP, Ilieș M, Melincovici CS, Spârchez M, Crăciun R, Nenu I, Horhat A, Tefas C, Spârchez Z, Iuga CA, Mocan T, Mihu CM. Novel approaches in search for biomarkers of cholangiocarcinoma. World J Gastroenterol 2022; 28(15): 1508-1525 [DOI: 10.3748/wjg.v28.i15.1508] [Reference Citation Analysis]
9 Niger M, Nichetti F, Dell'Angelo F, Cappelletti V, Pircher C, Vismara M, Cotsoglou C, Bhoori S, Vingiani A, Di Bartolomeo M, Pietrantonio F, de Braud F, Pruneri G, Daidone MG, Mazzaferro V. Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. JCO Precis Oncol 2022;6:e2100472. [PMID: 35319965 DOI: 10.1200/PO.21.00472] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku F. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol 2022;6:e2100197. [PMID: 35171660 DOI: 10.1200/PO.21.00197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cho MT, Gholami S, Gui D, Tejaswi SL, Fananapazir G, Abi-jaoudeh N, Jutric Z, Samarasena JB, Li X, Valerin JB, Mercer J, Dayyani F. Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. Cancers 2022;14:392. [DOI: 10.3390/cancers14020392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Manne A, Woods E, Tsung A, Mittra A. Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology. Front Oncol 2021;11:768009. [PMID: 34868996 DOI: 10.3389/fonc.2021.768009] [Reference Citation Analysis]
13 Rizzo A, Ricci AD, Gadaleta-caldarola G, Brandi G. Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies. Expert Review of Precision Medicine and Drug Development. [DOI: 10.1080/23808993.2021.2008144] [Reference Citation Analysis]
14 Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther 2021;14:5145-60. [PMID: 34720591 DOI: 10.2147/OTT.S272208] [Reference Citation Analysis]
15 Chen C, Wang T, Yang M, Song J, Huang M, Bai Y, Su H. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer. Pathol Oncol Res 2021;27:1609879. [PMID: 34720757 DOI: 10.3389/pore.2021.1609879] [Reference Citation Analysis]
16 Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, El-Shemerly M, Dimova-Dobreva M, Polyakova I, Häckl M, Zhou P, Lane H, Kellenberger L, Engelhardt M. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs 2021;30:1071-80. [PMID: 34698609 DOI: 10.1080/13543784.2021.1995355] [Reference Citation Analysis]
17 Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Rev Clin Pharmacol 2021;14:1233-52. [PMID: 34591728 DOI: 10.1080/17512433.2021.1947246] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Moati E, Taly V, Garinet S, Didelot A, Taieb J, Laurent-Puig P, Zaanan A. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. Cancers (Basel) 2021;13:4743. [PMID: 34638228 DOI: 10.3390/cancers13194743] [Reference Citation Analysis]
19 Shotton R, Lamarca A, Valle J, McNamara MG. Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. World J Gastrointest Oncol 2021; 13(9): 1073-1085 [PMID: 34616513 DOI: 10.4251/wjgo.v13.i9.1073] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Hack SP, Zhu AX. Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:1007-15. [PMID: 34459336 DOI: 10.1080/13543784.2021.1974838] [Reference Citation Analysis]
21 Thornblade LW, Wong P, Li D, Warner SG, Chang S, Raoof M, Kessler J, Amini A, Lin J, Chung V, Singh G, Fong Y, Melstrom LG. Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers (Basel) 2021;13:4062. [PMID: 34439216 DOI: 10.3390/cancers13164062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Nesic M, Bødker JS, Terp SK, Dybkær K. Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples. Biomed Res Int 2021;2021:5585148. [PMID: 34307658 DOI: 10.1155/2021/5585148] [Reference Citation Analysis]
23 Israel MA, Danziger N, McGregor KA, Murugesan K, Gjoerup O, Sokol ES, Tukachinsky H, Kurzrock R, Kato S, Sicklick JK, Nimeiri HS, Oxnard GR, Ross JS. Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. Oncologist 2021;26:787-96. [PMID: 34080753 DOI: 10.1002/onco.13844] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
24 Wintachai P, Lim JQ, Techasen A, Lert-Itthiporn W, Kongpetch S, Loilome W, Chindaprasirt J, Titapun A, Namwat N, Khuntikeo N, Jusakul A. Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. Diagnostics (Basel) 2021;11:999. [PMID: 34070951 DOI: 10.3390/diagnostics11060999] [Reference Citation Analysis]
25 Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2368. [PMID: 34072277 DOI: 10.3390/jcm10112368] [Reference Citation Analysis]
26 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
27 Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020;17:441-452. [PMID: 32859625 DOI: 10.21873/cgp.20203] [Cited by in Crossref: 38] [Cited by in F6Publishing: 60] [Article Influence: 38.0] [Reference Citation Analysis]
28 Angelakas A, Lamarca A, Hubner RA, McNamara MG, Valle JW. Ivosidenib: an investigational drug for the treatment of biliary tract cancers. Expert Opin Investig Drugs 2021;30:301-7. [PMID: 33683991 DOI: 10.1080/13543784.2021.1900115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Kamp EJCA, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol 2021;14:17562848211002023. [PMID: 33948111 DOI: 10.1177/17562848211002023] [Reference Citation Analysis]
30 DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol 2021;15:471-4. [PMID: 33641586 DOI: 10.1080/17474124.2021.1896967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Reference Citation Analysis]
32 Chatchawal P, Wongwattanakul M, Tippayawat P, Jearanaikoon N, Jumniansong A, Boonmars T, Jearanaikoon P, Wood BR. Monitoring the Progression of Liver Fluke-Induced Cholangiocarcinoma in a Hamster Model Using Synchrotron FTIR Microspectroscopy and Focal Plane Array Infrared Imaging. Anal Chem 2020;92:15361-9. [PMID: 33170647 DOI: 10.1021/acs.analchem.0c02656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wijetunga I, McVeigh LE, Charalambous A, Antanaviciute A, Carr IM, Nair A, Prasad KR, Ingram N, Coletta PL. Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review. Cancers (Basel) 2020;12:E2817. [PMID: 33007872 DOI: 10.3390/cancers12102817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, Taylor C, McNamara MG, Hubner RA, Valle JW. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.J Clin Med. 2020;9. [PMID: 32899345 DOI: 10.3390/jcm9092854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
35 Smith R, Geary SM, Salem AK. Silicon Nanowires and Their Impact on Cancer Detection and Monitoring. ACS Appl Nano Mater 2020;3:8522-36. [DOI: 10.1021/acsanm.0c01572] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
36 Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.Cancers (Basel). 2020;12. [PMID: 32722188 DOI: 10.3390/cancers12082039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
37 Guo D, Yang L, Yang J, Shi K. Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer (NSCLC). Medicine (Baltimore) 2020;99:e20431. [PMID: 32590728 DOI: 10.1097/MD.0000000000020431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Zhao EY, Bratman SV. Emerging Precision Oncology Applications of Liquid Biopsy using Circulating Tumour DNA and Methylome Profiling. Clin Oncol (R Coll Radiol) 2020;32:626-31. [PMID: 32586654 DOI: 10.1016/j.clon.2020.05.022] [Reference Citation Analysis]
39 Ma J, Feng J, Zhou X. Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway. Exp Mol Pathol 2020;115:104466. [PMID: 32446859 DOI: 10.1016/j.yexmp.2020.104466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol 2020;73:170-85. [PMID: 32171892 DOI: 10.1016/j.jhep.2020.03.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 37.5] [Reference Citation Analysis]